TScan Therapeutics, Inc. financial data

Symbol
TCRX on Nasdaq
Location
880 Winter Street, Waltham, MA
Fiscal year end
December 31
Latest financial report
10-Q - Q3 2025 - Nov 12, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 758 % +4.42%
Debt-to-equity 63.8 % +1.3%
Return On Equity -73.9 % -25.8%
Return On Assets -45.1 % -25.2%
Operating Margin -1.77K % -38.3%

Shares

Label TTM Value / Value Unit Change %
Entity Public Float 202B USD +270608%
Weighted Average Number of Shares Outstanding, Basic 130M shares +9.38%
Weighted Average Number of Shares Outstanding, Diluted 130M shares +9.38%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 8.42M USD -10%
Research and Development Expense 123M USD +23%
General and Administrative Expense 33.6M USD +18.3%
Operating Income (Loss) -149M USD -24.4%
Net Income (Loss) Attributable to Parent -143M USD -28.1%
Earnings Per Share, Basic -1 USD/shares -109%
Earnings Per Share, Diluted -1 USD/shares -109%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 170M USD +27.3%
Marketable Securities, Current 14.9M USD -89.2%
Accounts Receivable, after Allowance for Credit Loss, Current 31.9M USD
Assets, Current 188M USD -31.3%
Property, Plant and Equipment, Net 9.3M USD +24.7%
Operating Lease, Right-of-Use Asset 59.4M USD -0.34%
Assets 262M USD -24.7%
Accounts Payable, Current 6.35M USD +74.2%
Employee-related Liabilities, Current 5.76M USD +19.9%
Liabilities, Current 29.2M USD +1.91%
Operating Lease, Liability, Noncurrent 56.3M USD +0.88%
Other Liabilities, Noncurrent 278K USD +90.4%
Liabilities 118M USD -0.62%
Accumulated Other Comprehensive Income (Loss), Net of Tax 2K USD
Retained Earnings (Accumulated Deficit) -482M USD -42%
Stockholders' Equity Attributable to Parent 144M USD -37.1%
Liabilities and Equity 262M USD -24.7%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -37.6M USD -28.4%
Net Cash Provided by (Used in) Financing Activities -525K USD -303%
Net Cash Provided by (Used in) Investing Activities 13.5M USD -62.6%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -24.6M USD -444%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 175M USD +26.3%
Interest Paid, Excluding Capitalized Interest, Operating Activities 569K USD -24.9%
Deferred Tax Assets, Valuation Allowance 122M USD +47.8%
Operating Lease, Liability 65.3M USD +4.69%
Depreciation 678K USD -45.9%
Payments to Acquire Property, Plant, and Equipment 1.53M USD +117%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -143M USD -19.5%
Lessee, Operating Lease, Liability, to be Paid 94.1M USD -1.9%
Property, Plant and Equipment, Gross 25.9M USD +16.1%
Operating Lease, Liability, Current 6.9M USD +77.1%
Lessee, Operating Lease, Liability, to be Paid, Year Two 13M USD +23.8%
Lessee, Operating Lease, Liability, to be Paid, Year One 10.1M USD +6.12%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 28.8M USD -14.2%
Lessee, Operating Lease, Liability, to be Paid, Year Three 13.3M USD +21.8%
Deferred Tax Assets, Operating Loss Carryforwards 31.3M USD +35%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10M shares 0%
Unrecognized Tax Benefits 0 USD
Lessee, Operating Lease, Liability, to be Paid, Year Four 13.7M USD +21.8%
Preferred Stock, Shares Outstanding 0 shares
Deferred Tax Assets, Net of Valuation Allowance 139M USD +39.7%
Interest Expense 2.85M USD -23.4%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%